The rapid ascent of antibody-drug conjugates (ADCs) represents perhaps the most significant paradigm shift in oncology therapeutics this decade. By combining the specificity of monoclonal antibodies with the lethal efficiency of cytotoxic chemotherapy, ADCs have transformed the treatment landscape for a variety of solid tumors. With approximately 15 FDA-approved products now on the market and a sector valuation projected to reach $57 billion by 2032, the momentum is undeniable.
Yet, a persistent clinical enigma remains: why do tumors that appear “target-positive” in standard pathology assays frequently fail to respond to these sophisticated therapies? This critical gap between diagnostic detection and therapeutic efficacy is the focus of a high-stakes collaboration between Gilead Sciences and the spatial biology leader, Nucleai.
The "GPS" Fallacy: When Targeted Therapy Misses the Mark
The foundational promise of ADCs is elegance itself. By attaching a cytotoxic payload to an antibody, clinicians can theoretically deliver a high-dose "payload" directly to a cancer cell while sparing healthy tissue. As Dr. Ken Bloom, head of pathology at Nucleai, succinctly describes it: “Initially, what we were told was that ADCs are basically targeted chemotherapy. I’m going to put a GPS signal on my beachhead, on my chemotherapy target, and it’s going to zone in just to the tumor cells and release its payload.”
In practice, however, the biology of the tumor microenvironment (TME) is rarely so accommodating. A tumor may appear target-positive on a conventional immunohistochemistry (IHC) slide, but the reality for the drug is far more complex. Several mechanisms of resistance have been identified:
- Target Accessibility: The cell-surface target may be physically masked, truncated, or structurally altered.
- Premature Payload Release: Extracellular proteases within the TME can cleave ADC linkers before the drug reaches its intended target.
- Active Defense Mechanisms: Cancer cells have evolved sophisticated drug-efflux pumps designed to expel toxic payloads, rendering the ADC ineffective even after successful internalization.
Chronology of a Strategic Collaboration
The partnership between Gilead and Nucleai marks an evolution from traditional drug development to a data-centric, spatial-biology approach.
- Early Stages (Pre-2024): The relationship originated in preclinical research, primarily focusing on multiplex immunofluorescence (mIF). These initial studies sought to map the complex interactions within the TME, establishing the utility of spatial analysis in understanding drug behavior.
- Expansion (2024–2025): Recognizing the potential to extract more value from existing clinical assets, the collaboration deepened to include retrospective analysis of clinical-trial datasets.
- The August 2026 Disclosure: The companies publicly announced that Nucleai has processed whole-slide images (both H&E and IHC) from several of Gilead’s oncology clinical studies. By linking these high-resolution tissue features with longitudinal clinical outcomes, the team has begun to identify patterns that traditional pathology overlooks.
The "Inside-Outside" Epitope Problem
One of the most profound revelations in this partnership concerns the limitations of current diagnostic standards. For decades, pathologists have relied on IHC to measure protein expression. However, most antibodies used in clinical pathology are designed to target the intracellular domain of a membrane protein.
"There’s a reason that we look at the internal side as pathologists, that we try to stay inside the membrane," explains Dr. Bloom. "Tissue processing tends to preserve the intracellular portions of membrane proteins better than their extracellular regions."
This creates a fundamental disconnect. While a pathologist is looking at the inside of the cell to confirm the presence of a marker like HER2, the ADC is navigating the extracellular space, attempting to bind to the outer portion of that same protein. If the extracellular domain is shed, glycosylated, or truncated—as is common with HER2 variants like p95HER2—the ADC cannot bind, even if the IHC assay reports a "positive" result.
This discordance has been documented in clinical literature, with studies indicating that up to 15% of breast cancer patients show significant discrepancies between intracellular and extracellular target expression, directly impacting disease-free survival.
Redefining Pathology: The Computational Frontier
The collaboration between Gilead and Nucleai is pushing the boundaries of what is possible through computational pathology. While digital pathology has historically focused on digitizing slides for easier remote viewing, computational pathology aims to extract actionable, quantitative data that human eyes cannot process.
The Power of "Neighborhoods"
Modern computational analysis allows researchers to move beyond simply counting positive cells. It now enables the mapping of the "cellular neighborhood." By analyzing the density, spatial distribution, and proximity of immune cells, tumor cells, and stromal components, researchers can gain a holistic view of the tumor’s immune architecture. This context is essential for understanding why two tumors with identical biomarker scores may behave differently under ADC treatment.
AI as an "Overreader"
Dr. Bloom emphasizes that computational tools are not intended to replace the pathologist but to augment their capabilities. By acting as an "AI overreader," these tools reduce the cognitive burden of manual scoring, which is notoriously susceptible to fatigue and inter-observer variability.
"When you bring an AI overreader into the process, everything gets better," Bloom notes. "It catches mistakes. It gets all pathologists more uniform, which was always a big problem."
Implications for Future Oncology Trials
The implications of this work extend far beyond the current Gilead-Nucleai partnership. If successful, this approach could redefine how patients are selected for clinical trials and, ultimately, how they are matched to specific therapies.
Improving Clinical Trial Efficiency
By identifying candidate biomarkers that are more predictive than standard IHC, the team aims to create a more efficient recruitment process. Instead of broad inclusion criteria based on crude expression levels, future trials could use spatial biomarkers to identify patients most likely to respond to specific ADC constructs.
Bridging the Communication Gap
One of the more practical benefits of computational pathology is visualization. Traditional pathology reports are often dense, text-heavy documents that can be difficult for oncologists to translate into clinical decisions. Computational tools offer the ability to "paint" tissue images, providing an intuitive, color-coded visual representation of the tumor microenvironment that can be easily understood by the entire multidisciplinary clinical team.
The Road Ahead: Establishing a New Standard
Despite the promise, the industry remains in a period of experimentation. Dr. Bloom acknowledges that while several pharmaceutical leaders are investing in this space, a standardized, repeatable pathway for clinical adoption has yet to be fully established.
"I think there still isn’t a pathway that’s been forged clearly yet for somebody else to follow," Bloom says. "But the good news is that there are several leaders out there attempting to forge that first path. What you’re going to see, as soon as the first one hits, is a wave that follows."
For now, the focus remains on rigorous validation. Gilead and Nucleai are expected to present findings from their retrospective analyses in late 2026 or early 2027. These data will likely serve as a proof-of-concept for the industry, demonstrating that the future of precision medicine lies not just in finding the target, but in understanding the complex, spatial reality of the tumor microenvironment.
As ADC technology matures, the ability to look "outside the membrane" and understand the architectural context of a tumor will become the next great differentiator in oncology. By shifting the focus from static protein expression to dynamic spatial biology, Gilead and Nucleai are effectively setting the stage for a new generation of more precise, more effective cancer treatments.
About the Author
